across drug and device components.

Risk-Based Approach: Strategy focusing regulatory attention and resources on higher-risk product modifications.

These definitions form the backbone of global lifecycle compliance strategies for combination products.

Regulatory Frameworks Governing Lifecycle Management

Different jurisdictions impose overlapping but distinct requirements:

• FDA (US): Requires supplements (CBE-30, PAS) for post-approval drug changes, and QSR compliance for device modifications. The Office of Combination Products coordinates review.
• EMA (EU): Under EU MDR, drug-device combinations require conformity assessments for device components and updated Marketing Authorisation Applications (MAAs) for medicinal changes.
• CDSCO (India): MDR 2017 and Schedule Y govern device and drug changes. CDSCO mandates notification of modifications and periodic safety updates.
• ROW Markets: Japan (PMDA) and China (NMPA) require simultaneous lifecycle submissions for both drug and device aspects.

RA professionals must design lifecycle strategies that address both drug and device components across multiple global frameworks.

Processes and Workflow for Lifecycle Management

A structured workflow for lifecycle management includes:

1. Change Identification: Detect potential modifications through internal quality systems, market feedback, or regulatory changes.
2. Impact Assessment: Evaluate effect of changes on safety, efficacy, and performance across drug and device elements.
3. Regulatory Classification: Determine submission type (e.g., FDA PAS, EMA Type II variation, CDSCO major change).
4. Dossier Preparation: Compile updated CTD/eCTD modules and device technical documentation.
5. Submission & Review: File with appropriate authority and respond to queries during evaluation.
6. Implementation: Roll out approved changes with updated labeling, packaging, or device modifications.
7. Post-Market Monitoring: Continue pharmacovigilance and device vigilance activities.

This workflow ensures efficient and compliant lifecycle management across regions.

Case Study 1: FDA Lifecycle Management

Case: In 2023, a company updated the injector mechanism of a prefilled biologic product.

• Challenge: FDA classified the change as a Prior Approval Supplement (PAS), requiring extensive data.
• Action: Submitted PAS with updated human factors study and device master file cross-references.
• Outcome: FDA approved the modification after a 10-month review cycle.
• Lesson Learned: Device modifications often escalate submission category and timelines.

Case Study 2: EU Lifecycle Management under MDR

Case: A European company modified packaging for a drug-device inhaler combination.

• Challenge: EMA required demonstration of continued device conformity under MDR Annex I.
• Action: Submitted updated MAA including device conformity certificates and risk assessments.
• Outcome: EMA approved modification contingent on periodic post-market clinical follow-up.
• Lesson Learned: Even minor packaging changes trigger additional documentation under MDR.

Tools, Templates, and Systems Used

Lifecycle management requires advanced regulatory resources:

• Change Control Templates: Document formats for recording and assessing modifications.
• Regulatory Information Management (RIM) Systems: Digital platforms tracking submissions and lifecycle changes across regions.
• Device Technical Documentation Templates: MDR-compliant structures for device updates.
• Inspection Readiness Checklists: SOPs ensuring consistent quality management across pharma and device components.
• Post-Market Surveillance Tools: Systems to manage pharmacovigilance and device vigilance reporting.

These tools enable RA professionals to maintain compliance during the lifecycle of combination products.

Common Challenges and Best Practices

Managing lifecycle for combination products is resource-intensive:

• Regulatory Overlap: Dual requirements from drug and device authorities complicate submissions.
• Documentation Burden: Maintaining updated CTD and device files requires continuous effort.
• Global Variability: Differences between FDA, EMA, and CDSCO frameworks create complexity.
• Inspection Risks: Agencies audit both GMP (drug) and ISO 13485 (device) compliance.

Best practices include aligning drug and device QMS systems, conducting regular mock audits, engaging in early dialogue with regulators, and adopting harmonized templates for efficiency.

Latest Updates and Strategic Insights

As of 2025, lifecycle management for combination products reflects several trends:

• eCTD 4.0 Adoption: Enhancing integration of device modules into drug submissions.
• Global Reliance Models: ROW markets increasingly relying on FDA/EMA lifecycle reviews.
• Digital Vigilance Tools: AI systems for adverse event signal detection across drug and device components.
• Human Factors Emphasis: Agencies requiring repeat usability testing for modified devices.
• Regulatory Convergence: ICH and IMDRF initiatives moving toward harmonized lifecycle change classifications.

Strategically, RA professionals must prepare for stricter post-approval obligations, greater reliance on digital tools, and harmonized regulatory expectations across global markets.

Conclusion

Lifecycle management of combination products requires multidisciplinary regulatory expertise spanning pharmaceuticals, devices, and biologics. By mastering post-approval change processes, integrating vigilance systems, and adopting harmonized tools, RA professionals can ensure compliance and sustain market presence. In 2025 and beyond, lifecycle strategies will define the success of combination products as regulators emphasize long-term safety, innovation, and quality assurance.